

3-12-08

CASE 4-31830C

1648/X

IFU

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 971832973 US

Express Mail Label Number

3/11/2008

Date of Deposit



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
MALCOLM RICHARD BOYD
APPLICATION NO: 09/884715
FILED: JUNE 19, 2001

Art Unit: 1648
Examiner: Peng, Bo

FOR: NUCLEOTIDE ANALOGS IN COMBINATION THERAPY OF
HERPES SIMPLEX INFECTIONS

MS: Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed May 27, 2005. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


Copies of these references are enclosed herewith.

03/12/2008 ATRINH 00000035 190134 09884715
01 FC:1806 180.00 DA

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-1202


Jennifer C. Chapman
Attorney for Applicant
Reg. No. 47,487

Date: *March 11, 2008*



CASE 4-31830C

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 441882973 US

Express Mail Label Number

3/11/2008

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1648

MALCOLM RICHARD BOYD

Examiner: Peng, Bo

APPLICATION NO: 09/884715

FILED: JUNE 19, 2001

FOR: NUCLEOTIDE ANALOGS IN COMBINATION THERAPY OF
HERPES SIMPLEX INFECTIONS

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-1202

Date: *March 11, 2008*

Jennifer C. Chapman
Jennifer C. Chapman
Attorney for Applicant
Reg. No. 47,487